Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
29.85
+0.36 (1.22%)
Sep 28, 2026, 4:00 PM EDT - Market closed
Amylyx Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | 87.37 | 380.79 | 22.23 | 0.29 | |
Revenue Growth | - | - | -77.05% | 1612.94% | 7700.00% | -56.15% |
Cost of Revenue | 92.45 | 90.4 | 228.72 | 153.63 | 96.44 | 44.04 |
Gross Profit | -92.45 | -90.4 | -141.35 | 227.16 | -74.21 | -43.76 |
Selling, General & Admin | 69.66 | 62.89 | 114.33 | 188.36 | 127.13 | 38.93 |
Operating Expenses | 69.66 | 62.89 | 114.33 | 188.36 | 127.13 | 38.93 |
Operating Income | -162.1 | -153.29 | -255.68 | 38.8 | -201.34 | -82.69 |
Interest & Investment Income | 10 | 9.3 | 13.81 | 16.16 | 4.29 | 0.04 |
Other Non Operating Income (Expenses) | -6.23 | -6.23 | -11.07 | -10.6 | -2.61 | 0.07 |
EBT Excluding Unusual Items | -157.57 | -150.22 | -252.94 | 44.36 | -199.66 | -82.58 |
Merger & Restructuring Charges | - | - | -22.85 | - | - | - |
Gain (Loss) on Sale of Investments | 5.53 | 5.53 | 9.86 | 9.94 | 2.06 | -0.12 |
Other Unusual Items | - | - | - | - | - | -5.23 |
Pretax Income | -152.05 | -144.69 | -302.14 | 54.3 | -197.6 | -87.93 |
Income Tax Expense | 0.05 | 0.05 | -0.39 | 5.03 | 0.77 | - |
Net Income | -152.09 | -144.74 | -301.74 | 49.27 | -198.38 | -87.93 |
Net Income to Common | -152.09 | -144.74 | -301.74 | 49.27 | -198.38 | -87.93 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 106 | 95 | 68 | 67 | 58 | 7 |
Shares Outstanding (Diluted) | 106 | 95 | 68 | 70 | 58 | 7 |
Shares Change | 36.47% | 38.78% | -2.64% | 19.65% | 788.13% | 8.37% |
EPS (Basic) | -1.43 | -1.53 | -4.43 | 0.73 | -3.39 | -13.35 |
EPS (Diluted) | -1.43 | -1.53 | -4.43 | 0.70 | -3.39 | -13.35 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -126.72 | -123.48 | -204.01 | 10.68 | -182.4 | -75.15 |
Free Cash Flow Per Share | -1.19 | -1.31 | -2.99 | 0.15 | -3.12 | -11.41 |
Gross Margin | - | - | -161.78% | 59.66% | - | - |
Operating Margin | - | - | -292.63% | 10.19% | -905.72% | -29013.33% |
Profit Margin | - | - | -345.36% | 12.94% | -892.38% | -30852.98% |
Free Cash Flow Margin | - | - | -233.50% | 2.80% | -820.50% | -26369.12% |
EBITDA | -161.73 | -152.77 | -254.77 | 39.89 | -200.85 | -82.64 |
EBITDA Margin | - | - | -291.60% | 10.48% | - | - |
D&A For EBITDA | 0.37 | 0.53 | 0.9 | 1.09 | 0.49 | 0.05 |
EBIT | -162.1 | -153.29 | -255.68 | 38.8 | -201.34 | -82.69 |
EBIT Margin | - | - | -292.63% | 10.19% | - | - |
Effective Tax Rate | - | - | - | 9.26% | - | - |
Revenue as Reported | - | - | - | - | 22.23 | 0.29 |
Advertising Expenses | - | - | - | 9.5 | 4.4 | - |